1. World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization Press; 2018.
https://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf
. Accessed 11 Jan 2019.
2. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis 2016 update. Geneva: World Health Organization Press; 2016.
https://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf
. Accessed 12 Dec 2018.
3. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization Press; 2014.
https://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_eng.pdf
. Accessed 14 Nov 2018.
4. Di Perri G, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother. 2004;54:593–602.
5. Deshpande D, Alffenaar JWC, Köser CU, Dheda K, Chapagain ML, Simbar N, et al. d-Cycloserine pharmacokinetics/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a Faustian deal. Clin Infect Dis. 2018;67:S308–16.